rs243865 — MMP2 C-1306T

The ECM Dimmer Switch: How rs243865 Controls MMP-2 Production

Matrix metalloproteinase-2 (MMP-2), also called gelatinase A, is the body's primary enzyme for dissolving type IV collagen — the scaffolding that forms basement membranes throughout virtually every tissue. When fat cells expand, when capillaries branch, when wounds heal, MMP-2 is the molecular digger clearing the way by breaking down this dense collagen framework. MMP-2 is constitutively expressed and tightly regulated by a complex involving MT1-MMP (MMP14) and TIMP-2¹¹ MMP-2 is constitutively expressed and tightly regulated by a complex involving MT1-MMP (MMP14) and TIMP-2
Unlike most MMPs which require inflammatory induction, MMP-2 is always present in tissue at baseline, activated or inhibited depending on the local balance of its cofactors. In adipose tissue specifically, MMP-2 activity is essential for the ECM remodeling that accommodates fat-cell expansion; without it, adipocyte growth is constrained by a rigid collagen cage.

The rs243865 variant, a C→T transition at position –1306 of the MMP2 promoter, sits directly within an Sp1-binding site (CCACC box)²² Sp1-binding site (CCACC box)
Sp1 is a transcription factor that binds CCACC sequences in gene promoters to drive constitutive gene expression. The T allele destroys this binding site, reducing MMP-2 promoter activity by approximately 50% compared to the C allele. The result: TT carriers produce significantly less MMP-2 enzyme than CC carriers; CT heterozygotes are intermediate.

The Mechanism

This is a classic regulatory variant³³ regulatory variant
A variant that affects how much of a gene is produced, rather than altering the protein's structure or function. When the C allele is present, Sp1 binds normally and drives full MMP-2 transcription. The T allele disrupts this binding, resulting in lower baseline MMP-2 expression. Since MMP-2 protein structure is unchanged, whatever enzyme is produced by T allele carriers is fully functional — there is simply less of it.

In adipose tissue, the consequence is a shift in the balance between ECM rigidity and remodeling capacity. Low MMP-2 expression means slower breakdown of basement membrane collagen IV, reduced capillary sprouting, and impaired accommodation of expanding adipocytes. Over time, chronic low MMP-2 activity promotes ECM stiffness and fibrosis — hallmarks of lipedema pathology where progressive interstitial collagen accumulation and connective tissue thickening accompany uncontrolled lower-body adipose expansion. Lipedema adipose tissue shows significantly altered MMP expression including decreased MMP2, MMP9, and MMP11⁴⁴ Lipedema adipose tissue shows significantly altered MMP expression including decreased MMP2, MMP9, and MMP11
This parallels the reduced ECM remodeling capacity seen genetically in high-C-allele carriers.

Conversely, CC carriers with high MMP-2 production have more active ECM remodeling — providing more flexible tissue accommodation for fat cell expansion, but also potentially contributing to structural instability in other contexts (vessel walls, basement membranes in stressed tissues).

The Evidence

The functional consequence of this polymorphism was established in two landmark studies. Price et al. 2002⁵⁵ Price et al. 2002
781 lung cancer cases and 852 controls in a Chinese population; p < 0.001 for genotype association showed that CC genotype carried a 2.2-fold increased risk for lung cancer (OR 2.18, 95% CI 1.70–2.79), with the effect amplified 10-fold in heavy smokers. Ye et al. 2003⁶⁶ Ye et al. 2003
274 gastric cardia adenocarcinoma cases and 426 controls replicated the finding with an even larger effect (OR 3.36, 95% CI 2.34–4.97 for CC vs CT/TT). Both studies confirmed the functional mechanism: T allele disrupts the Sp1 site and reduces promoter activity by ~50%.

A 2015 meta-analysis⁷⁷ 2015 meta-analysis
29 case-control studies, 8,590 cancer cases and 9,601 controls across multiple cancer types confirmed the direction: CT genotype was significantly protective compared to CC (OR 0.758, 95% CI 0.637–0.902), and the dominant model (CT+TT vs CC) also showed protective effect (OR 0.816, 95% CI 0.678–0.982). The TT homozygous state did not show additional protection over CT, suggesting the primary benefit is from having at least one T allele to reduce Sp1 binding.

For body composition, Chang et al. 2011⁸⁸ Chang et al. 2011
546 New Zealand children aged 7 years; part of the CHDS cohort found that the C allele of rs243865 was associated with higher percentage body fat (estimate 1.40, 95% CI 0.16–2.64, p = 0.027), though this was attenuated after covariate adjustment (p = 0.055). The broader MMP-2 promoter haplotype including rs243865 remained significantly associated with body fat percentage after full adjustment (p = 0.040), indicating the C allele's effect on adipose ECM remodeling has measurable phenotypic consequences even in childhood.

The cardiovascular picture is more nuanced. A dedicated meta-analysis on coronary artery disease⁹⁹ meta-analysis on coronary artery disease
2,118 samples found no significant association between -1306 C/T and CAD risk overall (OR 0.93, 95% CI 0.78–1.10). However, a 2025 cross-sectional study in resistant hypertension¹⁰¹⁰ 2025 cross-sectional study in resistant hypertension
78 patients with treatment-resistant hypertension; small sample but detailed phenotyping found that T allele carriers had significantly lower ejection fraction (OR 8.1, 95% CI 1.3–51.4) and higher carotid artery stenosis prevalence (OR 4.5, 95% CI 1.1–20.1). In this high-cardiovascular-risk setting, lower MMP-2 expression may impair adaptive vascular remodeling.

Evidence level for this SNP is moderate: the functional mechanism is well-established and replicated across multiple systems, but most associations are from case-control studies with population-specific effects, and there are no clinical practice guidelines.

Practical Implications

For CC carriers (the majority), high MMP-2 production supports active ECM remodeling — helpful for normal adipose expansion, angiogenesis, and tissue adaptation, but potentially problematic when chronic inflammation drives sustained matrix degradation. Supporting connective tissue integrity through adequate vitamin C (collagen synthesis), omega-3 fatty acids (anti-inflammatory reduction of MMP overactivation), and protein intake to maintain the structural proteins that MMP-2 degrades becomes especially relevant.

For TT carriers, reduced MMP-2 expression means the ECM is less remodeled — which reduces cancer risk through slower basement membrane breakdown and tumor invasion, but may limit adipose tissue adaptability and reduce vascular remodeling capacity under cardiovascular stress. The reduced cancer risk from the T allele should not be confused with protection from cardiovascular fibrosis.

For the lipedema context specifically, both extremes create risk through different mechanisms: excess MMP-2 (CC) may drive uncontrolled remodeling and capillary fragility, while deficient MMP-2 (TT) impairs the orderly matrix remodeling needed to resolve fibrosis, potentially contributing to progressive tissue stiffening.

Interactions

rs243865 is part of a three-SNP haplotype block with rs243864 and rs243866¹¹¹¹ rs243864 and rs243866
These three promoter variants are in high linkage disequilibrium with each other; the GTA haplotype at all three positions was significantly associated with percentage body fat in children. Individual SNP effects at rs243865 alone may underestimate the true haplotype effect. The MMP-2/TIMP-2 axis is directly relevant: high TIMP-2 (from rs7201 polymorphisms) combined with low MMP-2 (TT at rs243865) would compound the ECM remodeling deficit. The interaction between MMP-2 and MMP-3 (rs3025058) is particularly relevant for connective tissue health — both enzymes target the same basement membrane substrates and their combined activity determines net matrix turnover rate.

Supervisor note — candidate compound interaction: carriers of low-MMP-2 (TT at rs243865) combined with high-MMP-3 expression (TT at rs3025058, 5A/5A) represent a potentially destabilizing combination — reduced type IV collagen clearance from MMP-2 deficiency alongside elevated MMP-3 stromelysin activity. The net effect on connective tissue stability would depend on which substrates each enzyme preferentially targets in a given tissue context.